Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unlocking Sulforaphane's Potential: Evgen's CEO Shares 2016 Plans

This article was originally published in Scrip

Executive Summary

Sulforaphane, a potential anticancer agent and neuroprotectant found in brassica vegetables, is the basis of newly listed Evgen Pharma's technology, Sulforadex. Evgen has created a synthetic version of the molecule with its technology, which it believes will be successful in treating types of cancer, multiple sclerosis (MS) and subarachnoid hemorrhage. Scrip's Lubna Ahmed spoke to Evgen's CEO Dr. Stephen Franklin to find out more about where the company started, its technology and what we should expect from Evgen moving into 2016.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel